Illumina (NASDAQ:ILMN – Get Rating) will be announcing its earnings results after the market closes on Tuesday, February 7th. Analysts expect the company to announce earnings of $0.25 per share for the quarter. Illumina has set its FY 2022 guidance at $2.35-$2.50 EPS and its FY22 guidance at $2.35-$2.50 EPS.Investors that are interested in participating in the company’s conference call can do so using this link.
Illumina (NASDAQ:ILMN – Get Rating) last released its earnings results on Thursday, November 3rd. The life sciences company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.29 by $0.05. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Illumina had a positive return on equity of 4.36% and a negative net margin of 88.40%. On average, analysts expect Illumina to post $2 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Illumina Trading Down 1.8 %
ILMN opened at $210.10 on Tuesday. The stock has a market cap of $33.05 billion, a PE ratio of -7.96 and a beta of 1.13. The company has a quick ratio of 0.72, a current ratio of 0.93 and a debt-to-equity ratio of 0.07. The business has a 50 day moving average of $206.17 and a 200-day moving average of $208.46. Illumina has a 52 week low of $173.45 and a 52 week high of $371.16.
Insider Transactions at Illumina
In other news, SVP Aimee L. Hoyt sold 871 shares of the firm’s stock in a transaction on Monday, January 9th. The stock was sold at an average price of $205.57, for a total value of $179,051.47. Following the transaction, the senior vice president now directly owns 2,796 shares in the company, valued at approximately $574,773.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, SVP Aimee L. Hoyt sold 871 shares of Illumina stock in a transaction on Monday, January 9th. The stock was sold at an average price of $205.57, for a total transaction of $179,051.47. Following the transaction, the senior vice president now directly owns 2,796 shares in the company, valued at $574,773.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Susan H. Tousi sold 500 shares of Illumina stock in a transaction on Tuesday, December 6th. The shares were sold at an average price of $212.63, for a total value of $106,315.00. Following the transaction, the senior vice president now owns 39,162 shares in the company, valued at $8,327,016.06. The disclosure for this sale can be found here. Insiders have sold a total of 2,371 shares of company stock worth $499,481 in the last ninety days. Insiders own 0.13% of the company’s stock.
Hedge Funds Weigh In On Illumina
Institutional investors and hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC lifted its position in shares of Illumina by 312.5% in the first quarter. Acadian Asset Management LLC now owns 2,013 shares of the life sciences company’s stock valued at $702,000 after acquiring an additional 1,525 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Illumina by 3.1% in the first quarter. Dimensional Fund Advisors LP now owns 237,118 shares of the life sciences company’s stock valued at $82,853,000 after acquiring an additional 7,114 shares in the last quarter. Dakota Wealth Management lifted its position in shares of Illumina by 13.8% in the first quarter. Dakota Wealth Management now owns 826 shares of the life sciences company’s stock valued at $288,000 after acquiring an additional 100 shares in the last quarter. Sequoia Financial Advisors LLC lifted its position in shares of Illumina by 16.9% in the first quarter. Sequoia Financial Advisors LLC now owns 803 shares of the life sciences company’s stock valued at $281,000 after acquiring an additional 116 shares in the last quarter. Finally, Baird Financial Group Inc. lifted its position in shares of Illumina by 10.2% in the first quarter. Baird Financial Group Inc. now owns 48,943 shares of the life sciences company’s stock valued at $17,108,000 after acquiring an additional 4,548 shares in the last quarter. 87.97% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on ILMN shares. Cowen lowered their target price on Illumina from $350.00 to $296.00 in a research note on Tuesday, January 10th. Citigroup lowered Illumina from a “neutral” rating to a “sell” rating and reduced their price objective for the company from $200.00 to $180.00 in a research report on Monday, December 12th. Bank of America reduced their price objective on Illumina from $220.00 to $210.00 in a research report on Tuesday, January 10th. OTR Global raised Illumina from a “mixed” rating to a “positive” rating in a research report on Tuesday, December 20th. Finally, Scotiabank began coverage on Illumina in a research report on Wednesday, January 4th. They set a “sector perform” rating and a $216.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $252.32.
About Illumina
Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.